You are here

Article Text

Article menu
Download PDFPDF
Letter
Peripheral visual field loss following treatment with etanercept
  1. L J Clifford,
  2. J D Rossiter
  1. Queen Alexandra Hospital, Portsmouth, UK
  1. Correspondence to: MrJonathan D Rossiter, Moorfields Eye Hospital City Road, London, EC1V 2PD, UK; jrossiterdoctors.org.uk

https://doi.org/10.1136/bjo.2003.036954

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Etanercept is a relatively new anti-tumour necrosis factor α (TNF-α) therapy for inflammatory arthritides. Although there may be an association with uveitis,1 there have been no reports of patients experiencing visual disturbance.2 We present a case of a patient who developed symptomatic bilateral peripheral visual field loss shortly after initiation of treatment with etanercept.

    Case report

    A 59 year old woman was referred complaining of bilateral, sequential peripheral visual field disturbance, which developed during a course of etanercept therapy for rheumatoid arthritis. Initially she noticed a left upper temporal field defect occurring the day after receiving the first injection of etanercept. Following the second injection she became aware of …

    View Full Text